The immunomodulatory capacity of mesenchymal stem cells

Gebler, Antje; Zabel, Olivia; Seliger, Barbara

doi:10.1016/j.molmed.2011.10.004

Cited by 317 publications

(277 citation statements)

References 56 publications

Supporting

Mentioning

263

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the published data demonstrating the secretion of IL-10 by MSCs are quite contradictory. Almost half of the papers discussed in the present review report positive secretion of IL-10 by MSCs [62,66,[81][82][83][84] , while the other half and our own experimental results reject such a possibility [60,64,69,78,[85][86][87][88] . It is quite logical to support the concept proposed by some authors claiming that MSCs secrete IL-10 under specific conditions with the inflammatory environment and presence of cytokines (IFNγ, IL-1b and TNFα) which activate certain Toll-like receptors on MSCs [63,65,67] .…”

Section: Introductionmentioning

confidence: 45%

Secretion of immunoregulatory cytokines by mesenchymal stem cells

Kyurkchiev

Bochev

Ivanova‐Todorova

et al. 2014

WJSC

528

392

View full text Add to dashboard Cite

According to the minimal criteria of the International Society of Cellular Therapy, mesenchymal stem cells (MSCs) are a population of undifferentiated cells defined by their ability to adhere to plastic surfaces when cultured under standard conditions, express a certain panel of phenotypic markers and can differentiate into osteogenic, chondrogenic and adipogenic lineages when cultured in specific inducing media. In parallel with their major role as undifferentiated cell reserves, MSCs have immunomodulatory functions which are exerted by direct cell-to-cell contacts, secretion of cytokines and/or by a combination of both mechanisms. There are no convincing data about a principal difference in the profile of cytokines secreted by MSCs isolated from different tissue sources, although some papers report some quantitative but not qualitative differences in cytokine secretion. The present review focuses on the basic cytokines secreted by MSCs as described in the literature by which the MSCs exert immunodulatory effects. It should be pointed out that MSCs themselves are objects of cytokine regulation. Hypothetical mechanisms by which the MSCs exert their immunoregulatory effects are also discussed in this review. These mechanisms may either influence the target immune cells directly or indirectly by affecting the activities of predominantly dendritic cells. Chemokines are also discussed as participants in this process by recruiting cells of the immune systems and thus making them targets of immunosuppression. This review aims to present and discuss the published data and the personal experience of the authors regarding cytokines secreted by MSCs and their effects on the cells of the immune system. © 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Mesenchymal stem cells; Immunomodulation; Cytokines; Chemokines; Dendritic cells Core tip: Autoimmune diseases affect approximately 5% of the human population, leading to serious disability and effective methods to treat these diseases are still not perfect. Mesenchymal stem cells (MSCs) are assumed to be promising agents, both for regenerative medicine and cell therapy for autoimmune disorders. Under the influence of some factors, mesenchymal stem cells secrete cytokines which induce suppression of the immune response. Studies on the secreted cytokines and the precise mechanisms involved in these suppressive mechanisms would create possibilities for efficient application of MSCs as a therapeutic means for treatment of autoimmune diseases.Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, REVIEWSubmit a

show abstract

Section: Introductionmentioning

confidence: 45%

Secretion of immunoregulatory cytokines by mesenchymal stem cells

Kyurkchiev

Bochev

Ivanova‐Todorova

et al. 2014

WJSC

528

392

View full text Add to dashboard Cite

show abstract

“…A variety of easy means of isolating and expanding these cells ex-vivo (bone marrow, 15,16 adipose tissue, 16,17 placenta, 18 peripheral blood, 19 and others) also makes MSCs useful cells for therapeutic approaches to supplementing tissue regeneration ( Table 2). Additionally, these cells have been shown to have notable immunomodulatory effects on the surrounding environment following transplantation, [29][30][31][32] and can support native cells with the secretion of a variety of pro-survival and pro-migratory cytokines and growth factors. 33,34 As a major problem in chronic wounding is unmitigated inflammation, this characteristic of MSCs has made them good candidates for approaches to cell therapy for chronic wounds in particular.…”

Section: Introductionmentioning

confidence: 99%

Activity of mesenchymal stem cells in therapies for chronic skin wound healing

2013

View full text Add to dashboard Cite

“…The immunomodulatory effect of MSCs was first indicated by long term engraftment in a xenogeneic environment in 2000 [10]. Although its mechanisms have not been fully understood, previous studies have revealed that MSCs inhibited the function of immune cells via cell to cell contact dependent mechanism and several soluble immune modulators [11][12][13][14].…”

Section: Immunomodulatory Function Of Mscsmentioning

confidence: 99%

“…In contrast, MSCs can promote the differentiation to M2 macrophages which abundantly produce IL-10 [13]. These modulations of immune cells are associated with many soluble factors released from MSCs, including transforming growth factor-β1, hepatocyte growth factor, IL-10, indoleamine 2, 3-dioxygenase, prostaglandin E2, nitric oxide, matrix metalloproteinases, HLA-G (Figure 1) [11][12][13][14]. The secretion of these factors from MSCs has been shown to be induced by IFN-γ alone, or in combination with tumor necrosis factor (TNF)-α, IL-1α, or IL-1β [23].…”

Section: Immunomodulatory Function Of Mscsmentioning

confidence: 99%

Human Mesenchymal Stem Cell Therapy for Acute Graft Versus Host Disease

Yoshioka¹,

Miura²

2016

Transl Med

View full text Add to dashboard Cite

Acute graft versus host disease (GVHD) is the most critical complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The understanding of major histocompatibility complex (MHC) and the development of acute GVHD prophylaxis have contributed to decreasing the incidence of severe acute GVHD. However, these progresses expand the chance of receiving allo-HSCT from human leukocyte antigen (HLA) mismatched donor. In addition, the expanding of indication for allo-HSCT to elderly patients or patients with organ dysfunction by the pervasiveness of reduced-intensity conditioning is associated with increased risk of acute GVHD. Unexpectedly, severe refractory acute GVHD can occur even in allo-HSCT from HLA matched sibling donor. The first line therapy for severe acute GVHD is corticosteroid, but the second line therapy has not been established and the prognosis of steroid-resistant acute GVHD remains poor. Recently, the efficacy of human bone marrow mesenchymal stem cell (MSC) therapy for steroid-resistant acute GVHD has been consistently reported. MSCs are approved as a cell therapy drug for steroid-resistant acute GVHD in some countries. We here review the history and the future of MSC therapy for acute GVHD.

show abstract

The immunomodulatory capacity of mesenchymal stem cells

Cited by 317 publications

References 56 publications

Secretion of immunoregulatory cytokines by mesenchymal stem cells

Secretion of immunoregulatory cytokines by mesenchymal stem cells

Activity of mesenchymal stem cells in therapies for chronic skin wound healing

Human Mesenchymal Stem Cell Therapy for Acute Graft Versus Host Disease

Contact Info

Product

Resources

About